Kiora Pharmaceuticals Inc (KPHMW) — SEC Filings
Kiora Pharmaceuticals Inc (KPHMW) — 33 SEC filings. Latest: 10-Q (Nov 7, 2025). Includes 14 8-K, 6 10-Q, 6 SC 13G.
View Kiora Pharmaceuticals Inc on SEC EDGAR
Overview
Kiora Pharmaceuticals Inc (KPHMW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: KIORA PHARMACEUTICALS INC reported a net income of $26,806 for the three months ended September 30, 2025, a significant improvement from a net loss of $3,413,326 in the same period of 2024. However, for the nine months ended September 30, 2025, the company posted a net loss of $4,318,633, a reversal
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 28 neutral, 1 mixed. The dominant filing sentiment for Kiora Pharmaceuticals Inc is neutral.
Filing Type Overview
Kiora Pharmaceuticals Inc (KPHMW) has filed 6 10-Q, 14 8-K, 1 DEF 14A, 1 10-K, 6 SC 13G, 5 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of KPHMW's 20 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $26,806 |
| EPS | N/A |
| Debt-to-Equity | 0.33 |
| Cash Position | $5,508,899 |
| Operating Margin | N/A |
| Total Assets | $29,863,454 |
| Total Debt | $7,452,712 |
Key Executives
- Brian M. Strem, Ph.D.
- Eric J. Daniels, M.D., M.B.A.
- Melissa Tosca, CPA
- First PEO
- Second PEO
- Dr. Michael L. Weiser
- Ms. Jennifer L. Simpson
- Rule 13d-1(b)
- Rule 13d-1(c)
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Kiora Pharmaceuticals often rely on external funding, collaborations, and successful product development to achieve profitability. The competitive landscape is intense, with established players and emerging biotechs vying for market share and innovation.
Top Tags
pharmaceuticals (6) · 10-Q (5) · financials (4) · corporate-action (3) · material-agreement (3) · 8-K (3) · Pharmaceuticals (2) · compliance (2) · executive-compensation (2) · management-change (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $26,806 | For the three months ended September 30, 2025, a swing from a $3.4M loss in Q3 2024. |
| Total Revenue | $0 | For the nine months ended September 30, 2025, down from $16.02M in 2024. |
| Net Loss | $4,318,633 | For the nine months ended September 30, 2025, compared to a $7.8M net income in 2024. |
| Research and Development Expenses | $7,852,267 | For the nine months ended September 30, 2025, an increase from $5.9M in 2024. |
| Cash and Cash Equivalents | $5,508,899 | As of September 30, 2025, an increase from $3.79M at December 31, 2024. |
| Short-Term Investments | $13,866,546 | As of September 30, 2025, a decrease from $22.99M at December 31, 2024. |
| Accumulated Deficit | $147,700,755 | As of September 30, 2025, indicating significant historical losses. |
| Cash Runway | Late 2027 | Company anticipates sufficient cash to fund operations until this period. |
| Commission File Number | 001-36672 | Identifies the company's SEC filing history |
| Fiscal Year End | 2024-12-31 | Reporting period for the 10-K |
| Filing Date | 2025-03-25 | Date the 10-K was submitted to the SEC |
| SEC File Number | 001-36672 | Identifies the company's filing with the SEC. |
| Report Date | 20250110 | The earliest event date reported in this 8-K filing. |
| Period End Date | 2024-09-30 | The report covers financial and operational data up to this date. |
| Previous Year End Date | 2023-12-31 | For comparative analysis |
Forward-Looking Statements
- {"claim":"KIORA PHARMACEUTICALS will continue to file routine compliance documents.","entity":"KIORA PHARMACEUTICALS, INC.","targetDate":"2024-12-31","confidence":"high"}
- {"claim":"Kiora Pharmaceuticals' stock price may see increased attention due to institutional interest.","entity":"Kiora Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kiora Pharmaceuticals Inc (KPHMW)?
Kiora Pharmaceuticals Inc has 33 recent SEC filings from Jan 2024 to Nov 2025, including 14 8-K, 6 10-Q, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KPHMW filings?
Across 33 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 28 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Kiora Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kiora Pharmaceuticals Inc (KPHMW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kiora Pharmaceuticals Inc?
Key financial highlights from Kiora Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KPHMW?
The investment thesis for KPHMW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kiora Pharmaceuticals Inc?
Key executives identified across Kiora Pharmaceuticals Inc's filings include Brian M. Strem, Ph.D., Eric J. Daniels, M.D., M.B.A., Melissa Tosca, CPA, First PEO, Second PEO and 4 others.
What are the main risk factors for Kiora Pharmaceuticals Inc stock?
Of KPHMW's 20 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Kiora Pharmaceuticals Inc?
Recent forward-looking statements from Kiora Pharmaceuticals Inc include guidance on {"claim":"KIORA PHARMACEUTICALS will continue to file routine compliance documents.","entity":"KIORA PHARMACEUTICALS, IN and 1 other predictions.